Cigna's most recent trend suggests a bearish bias. One trading opportunity on Cigna is a Bear Call Spread using a strike $162.50 short call and a strike $167.50 long call offers a potential 23.46% return on risk over the next 13 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $162.50 by expiration. The full premium credit of $0.95 would be kept by the premium seller. The risk of $4.05 would be incurred if the stock rose above the $167.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Cigna is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Cigna is bearish.
The RSI indicator is at 32.6 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Cigna
The Late Morning Rundown: April 3, 2019
Wed, 03 Apr 2019 16:02:08 +0000
CNBC brings you fast, accurate, and actionable business news and market updates.
Cigna lowers cost of insulin copays to $25 for 30-day supply for some members
Wed, 03 Apr 2019 13:01:11 +0000
Cigna is launching a new program that caps copays at $25 for a 30-day supply of insulin. The program is available starting Wednesday to roughly 700,000 members with diabetes. The average cost for a 30-day supply of insulin was previously $41.50, Cigna said.
Cigna launches program to cap out-of-pocket insulin costs at $25/month
Wed, 03 Apr 2019 11:23:56 +0000
U.S. lawmakers have pulled up healthcare companies over rising costs of medicine, with powerful committees in Congress holding hearings in January on insulin affordability. The program will be for eligible people with diabetes in participating health plans, the company said. Cigna, which bought pharmacy benefits manager Express Scripts last year, said it was partnering with insulin manufacturers to lower copayments to $25 at the point of sale.
Cigna, Express Scripts launch program to cap insulin costs at $25 for 30-day supply
Wed, 03 Apr 2019 10:42:00 +0000
Cigna Corp. and Express Scripts announced Wednesday its Patient Assurance Program, which caps costs for a 30-day supply of insulin at $25 for eligible people with diabetes. The average out-of-pocket cost in 2018 for users of insulin plans managed by Cigna and Express Scripts, which Cigna acquired in December, was $41.50 for a 30-day supply. "Together, Cigna and Express Scripts are now able to give people who rely on insulin greater affordability and cost predictability so they can focus on what matters most: their well-being," said Cigna's Chief Clinical Officer Steve Miller. Cigna's stock, which was still inactive in premarket trade, has tumbled 16.5% year to date, while the SPDR Health Care Select Sector ETF has gained 6.0% and the S&P 500 has climbed 14.4%.
Cigna and Express Scripts Introduce Patient Assurance Program to Cap Out Of Pocket Costs at $25 per 30-Day Insulin Prescription
Wed, 03 Apr 2019 10:30:00 +0000
Addressing the need for greater affordability and access to insulin, Cigna and Express Scripts today announced the launch of the Patient Assurance ProgramSM, which will ensure eligible people with diabetes in participating plans pay no more than $25 for a 30-day supply of insulin.
Related Posts
Also on Market Tamer…
Follow Us on Facebook